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Hydatidiform mole
P ZVANDASARA 
SUMMARY
This article critically reviews the current understand­
ing of the origin of hydatidiform mole. The pathogen­
esis, clinical presentation and diagnosis is discussed. 
Suction curettage and close patient follow up reduces 
the mortality and morbidity of the patients with this 
disease.
INTRODUCTION
Changes have occurred over the years in the under­
standing of the pathogenesis, classification and follow 
up management of benign gestational trophoblastic 
disease (Hydatidiform mole).
Hydatidiform mole is a benign gestational tropho­
blastic neoplasm which can potentially progress to 
choriocarcinoma.6 It arises from placental chorionic 
tissue of foetal origin, i.e. trophoblastic tissue. If in the 
normal formation of the placenta during pregnancy the 
trophoblastic tissue becomes highly proliferative this 
can result in the formation of a hydatidiform mole.
Trophoblastic tissue invades the myometrium and 
maternal blood vessels during the implantation and 
development of the placenta resulting in the formation 
of lakes. This increases the absorptive surface area for 
the matemofoetal transfer. During this invading pro­
cess some trophoblastic cells enter the uterine veins 
and blood stream resulting in embolization of tropho- 
blasts to the lungs. During parturition embolization of 
trophoblasts also occurs.
The presence of trophoblasts in the lungs therefore 
does not mean invasive malignancy.
Trophoblastic tissue of a mole like trophoblasts of a 
normal placenta produce a wide range of hormonal and 
protein compounds. The range includes oestrogen, 
progesterone, human placental lactogen, prolactin, preg-
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nancy specific globulin B1 SP1 and human chorionic 
gonadotrophin.13 HCG is a glycoprotein molecule made 
up of two chains A and B sub units. HCG is similar to' 
the pituary glycoproteins LH+FSH except its B sub­
unit. Apart from the gestational trophoblastic disease 
(Hydatidiform mole, Choriocarcinoma) there are HCG 
producing tumours. These are malignant teratoma, 
embryonic tumours and dsysgeminoma. Dysgeminoma 
produces HCG when it contains giant syncytio-tropho- 
blasts. The human chorionic gonadotrophin (HCG) has 
superseded all the other molar products as a perfect 
tumour market. HCG is used in the diagnosis and 
follow up management of hydatidiform mole. As long 
as the tumour cells are alive HCG will be produced and 
the quantity in urine or serum correlates with the 
number of viable tumour cells1. Specific radioimmu­
noassay methods have been developed to measure the 
B subunit of HCG and thus differentiation between 
HCG and LH/FSH/TSH can be made accurately par­
ticularly at low levels of these hormones.
Hydatidiform mole is classified into two distinct 
clinical types based on pathological and cytogenic 
studies. The two types are complete (classical) and 
partial moles.14
Complete moles: Complete moles have a macro­
scopic appearance of a large tumour with clusters of 
translucent vesicles filled with fluid i.e. the grape like 
vesicles.
The vesicles are one centimetre in diameter on 
average. On microscopy the villi are oedematous and 
avascular. The trophoblasts are hyperplastic with ana­
plasia. There is no microscopic or macroscopic evi­
dence of any embryo, amniotic membranes or umbili­
cal cord.7 The absence of foetal vessels differentiate a 
complete from a partial mole. Complete moles have 
been shown to be androgenetic. A proportion of com­
plete moles give rise to persistent disease or malignant 
transformation.
Partial mole: A partial mole is characterised by a 
normal chorionic villi with macroscopic or micro­
scopic evidence of a foetus. Microscopically normal 
placental tissue with focal trophoblastic hyperplasia 
scattered within the placenta is found. Foetal vessels 
are seen. A partial mole has to be differentiated from 
hydropic degenerative changes in an abortion. Cytoge­
netic studies have demonstrated triploid chromosomal 
constitution as discussed below. Partial moles are 
thought not to give rise to persistent or malignant 
transformation.
Invasive mole (Chorioadenoma destuens)'. This 
occurs when trophoblastic cells invade into or through 
the uterine wall. Although embolisation of tropho­
blasts can occur these are not m etastases. In 
choriocarcinoma sheets of malignant trophoblastic cells 
can be identified without any villous structure. The 
cells are large, anaplastic, irregular syncytial giant 
cells..
The risk of malignancy of gestational trophoblastic 
disease cannot be determined from the pathological 
appearance of the trophoblastic cells. The management 
of molar pregnancy depends on the HCG levels rather 
than its malignant potential on the histological appear­
ances.
Pathogenesis of hydatidiform mole: The exact 
cause of hydatidiform mole remains unknown and it is 
thought to be a multistage process. The pathogenetic 
process is established at the time of conception linked 
to a defective ovum resulting in abnormal structure and 
function of the trophoblasts.12 Serial ultrasonographic 
studies of early pregnancy supports the theory that a 
molar pregnancy arises from an abnormal blighted 
ovum embryo which is followed by accumulation of 
fluid in the villi and trophoblastic proliferation.10
Cytogenetic studies of molar chromosomes has led 
to the discovery that the majority of complete moles 
have paternal chromosomal karyotype of 46 XX. The 
two X chromosomes are derived from the male partner. 
This results from fertilisation of an empty ovum by 
haploid sperm with 23 X chromosomes.
Subsequent duplication of the fertilised egg results 
in a 46 XX diploid number.
A 46 XY karyotype has been demonstrated in a 
minority of complete moles. This occurs from dispermia
i.e. two spermatoza with 23 XY and 23 XX fertilises an 
empty egg. The mechanism of how the female haploid 
chromosomes are lost is not known. Partial moles on 
the other hand were found to have triploid or trisomy 
chromosomal pattern.9 This occurs when a normal egg 
is fertilised by two sperm (double paternal contribu­
tion).
Studies have shown a higher incidence of the disease 
in the older age group i.e. over 40 years3 and the young 
age group under 20 years. Bagshawe (1986) showed 
that the risk of hydatidiform mole was six times greater 
in pregnancies occurring under 1S years of age and 400 
times greater for those over 50 years. Previous molar 
pregnancy increases the risk of another molar preg-
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nancy. Various authors have found different recur­
rence rates; one in 150, one in 50 and one in 762. The 
Charing Cross (UK) series have shown that one molar 
pregnancy increases the risk of a second one by 10 fold 
and a second molar pregnancy is associated with a 
further 10 fold increase of another hydatidiform mole.
The incidence of hydatidiform mole in the world is 
variable due to genetic, geographical, racial and envi­
ronmental influence. The disease is more common in 
the Fast East; Indonesia one in 200 pregnancies whilst 
in the United Kingdom the incidence is reported as one 
in 500 pregnancies.15 Parity has not been shown to be 
a high risk factor in hydatidiform mole.2
A high index of suspicion is required to diagnose 
hydatidiform  m ole before the passage of the 
pathognomonic grape like products because the signs 
and symptoms are often those of early pregnancy. 
Hydatidiform mole should be considered in the differ­
ential diagnosis of vaginal bleeding in early pregnancy. 
The vaginal bleeding in hydatidiform mole commonly 
occurs around the 12 weeks of pregnancy. Severe life 
threatening haemorrhage leading to hypovolaemic 
shock and deaths have been reported. Management of 
hydatidiform mole has to be in a hospital with sufficient 
blood bank back up.
Hyperemesis gravidarum is a common symptom. 
The vomiting associated with hydatidiform mole is due 
to high circulating HCG levels and the enlarging uterus 
pressing on the abdominal viscera.
The early onset of PET before 20 weeks of preg­
nancy is a strong pointer to molar pregnancy. A 70 pc 
incidence of pre-eclampsia in association with a large 
rapidly growing uterus has been documented. Pre­
eclampsia in association with hydatidiform mole is due 
to excessive trophoblastic activity and hormonal im­
balance although Scott et al attributes the cause to the 
presence of paternally derived chromosomes in molar 
pregnancy.
Hyperthyroidism associated with molar pregnancy 
is due to the production by trophoblastic cells of a 
thyrotropin hormone which stimulates thyroid hor­
mone production. In the mild form of the disease; 
tremor, tachycardia or nervousness can occur. In severe 
thyrotoxicosis however congestive cardiac failure, 
goitre or weight loss can develop. Evacuation of the 
molar pregnancy is usually accompanied by spontane­
ous resolution of the thyrotoxicosis.
A partial mole can co-exist with a live foetus and thus 
a foetal heart can be heard.4 Generally the foetus
359
associated with a partial mole tends to die in early 
gestation.
Uteri greater than 16 weeks or four weeks greater 
than the missed period are associated with a higher 
incidence of trophoblastic embolization.
The diagnosis of embolization can be confiimed by 
the demonstration of villous trophoblasts in the pulmo­
nary vasculature at autopsy or from blood obtained 
from the pulmonary artery by Swan Ganz Catheter. The 
incidence of embolization has been found to be 2,6 pc 
and 5,4 pc.17 Patients who develop pulmonary 
embolization subsequently develop trophoblastic 
neoplasia. Fourteen pc and 20 pc incidence were found 
by Curry et al and Howie respectively.-5
Ovarian cysts found in association with large for 
dates uteri have a high incidence of malignant tropho­
blastic sequelae. The ovarian cysts are the theca lutein 
which are caused by a high HCG level.
A positive pregnancy test is not diagnostic of a 
hydatidiform mole and neither is one HCG titer.
The HCG titer in normal singleton pregnancy show 
a wide variation and rises from the first week of 
conception to peak between 50-70 days, falling there­
after to low levels. The levels fall after 80 to 90 days of 
pregnancy.5
The peak serum levels are in the region of 120-160 
iu/ml. High HCG levels are also found in molar preg­
nancies and racial difference in HCG titers have been 
demonstrated. In multiple pregnancy the HCG levels 
are higher. Due to this wide titer variation the diagnosis 
of molar pregnancy cannot be made on a single sample. 
Sequential samples showing progressive increase in 
HCG titers or titers over 1000 iu/ml are suggestive of 
hydatidiform mole.1516 However, this method has been 
superceeded by ultrasound scanning of the uterus as a 
diagnosis of molar pregnancy in those centres with 
ultrasound.
Ultrasound scanning can be used in the first trimester 
and can be repeated if the diagnosis is in doubt. In 
centres where the ultrasound machine is available, it 
should be used as a standard diagnostic technique for 
molar pregnancy.
The features of hydatidiform mole on ultrasound 
scanning are:-
a) Snow storm appearance - this picture is produced 
by the echoes from the vesicular molar tissue. Small 
white dots and dashes are seen on the scan. 
However, early placental development can mimic 
the presence of a hydatidiform mole and this neces­
sitates scanning the entire cross section of the uterus 
to exclude the presence of foetal parts.
k
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b) In hydatidiform mole, no foetal echoes or foetal 
heart can be demonstrated. In multiple pregnancy 
misdiagnosis can occur because the size of the 
uterus will not be proportional to the gestation. 
Serial repeat ultrasound studies are advisable when 
a developing foetus is suspected. Misdiagnosis are 
rare in experienced ultrasonographer’s hands. 
Ultrasound scanning is useful in the diagnosis of a 
partial mole especially in the presence of a viable 
foetus.
Large hom ogenous solid ovarian teratoma, 
lymphoma or dysgerminoma can be misdiagnosed as 
hydatidiform mole on ultrasonography.8
X ray of the pelvis at 16 weeks can be helpful in 
centres where ultrasound scan is not available. At 16 
weeks the foetal skeleton will show on X ray. In 
multiple pregnancy or wrong dates the foetal skeleton 
may not show.
DIC is a known complication of hydatidiform mole. 
DIC is caused by embolization of trophoblasts to the 
lungs where they release thromboplastin substances 
into the circulation. Thromboplastin stimulates fibrin 
and platelet deposition into the blood vessels leading to 
consumption coagulatory.
Spontaneous abortion of a mole does occur and is 
associated with a low complication rate. In young 
patients dilatation suction curettage is the primary 
treatment when the cervix is closed. Suction curettage 
is the method preferred for the molar evacuation3 
because of the following advantages:-
a) Rapid evacuation of the uterus is achieved with 
minimal blood loss.
b) The danger of perforating the uterus is minimised as 
the instrument is blunt and no force is needed.
c) The danger of blood vessel injury is minimised and 
this reduces the chances o f trophoblastic 
embolization. The direction of the evacuation is 
outward into the suction tubing.
d) Suction curettage and spontaneous abortion are 
associated with a low risk of requiring chemo­
therapy for gestational malignancy when compared 
to patients who had a medical induction with oxy­
tocin, prostaglandin or hysterotomy.2 Displacement 
of trophoblasts into the intravascular space by uter­
ine contraction or manipulation occurs and this 
could account for the necessity to use chemo­
therapy.
e) Suction curettage can be safely used for large uter­
ine sizes. The uterus contracts immediately with or 
without the help of oxytocin making furthercurettage 
safer.
DIC following rapid suction evacuation has been 
reported. Hysterectomy can be considered in older 
women who have completed their family but however 
it does not eliminate the post molar incidence of malig­
nancy. Close follow up using HCG measurement will 
still need to be done. Hysterectomy decreases the 
chance of precipitating trophoblastic embolization since 
manipulation of the uterus is minimal.
In 90 pc of women with molar pregnancy, the tropho­
blasts regress after the evacuation.2 However, in a small 
proportion up to 10 pc of the tissue persists in the uterus 
or elsewhere for years and it is important to recognise 
these women.
Close follow up of molar pregnancy is of paramount 
importance. Complete mole should be followed up for 
the fust two years and partial mole for at least six 
months.2 Follow up is aimed at early detection of 
persistent disease so that chemotherapy can be initiated 
early thus improving the prognosis.
Bagshawe (1986) estimates that 7 to 7,5 pc of pa­
tients with molar pregnancy require chemotherapy 
after evacuation of the uterus. In the United States of 
America, the figures are much higher ranging from 20 
pc to 26 pc.
Indications for chemotherapy for patients who have 
had a hydatidiform made are as follows:1
1. Urinary HCG values greater than 30000 iu/1 HCG/ 
24 hour urine serum greater than 20 000 iu/1 at four 
to six weeks after evacuation of the mole.
2. Progressively rising HCG at any time post evacua­
tion of a mole.
3. Raised HCG at any time post evacuation of the 
mole.
4. Evidence of intracranial, hepatic, gastro-intestinal 
metastases.
5. Pulmonary metastases with persisting or rising HCG 
values.
6. Persistent uterine haemorrhage with a raised HCG 
value.
Systems to improve follow up of patients with molar 
disease have been set up in the United Kingdom. 
Patients with hydatidiform mole are registered at re­
gional centres. The registration process aims at im­
proving data collection and providing economical 
centralised HCG measurement. Counselling of the
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patients can be done and this increases patient compli­
ance. The knowledge of the natural history of the 
disease is enhanced. At each follow up visit, history of 
vaginal bleeding, vomiting and haemoptysis is ob­
tained. Abdominal examination for vaginal secondar­
ies, subinvoluted uterus and presence of thecalutein 
cysts will be determined.
Follow up B HCG determinations should be done 
twice weekly until normal HCG levels then monthly 
for six months and twice monthly for one year. A 
pregnancy test is only useful when positive but has no 
value in accurately assessing the course of the disease 
when negative. The sensitivity of the biologic/immu- 
nological pregnancy test in current use is in the region 
of 850-5 000 iu/1 HCG titer." The normal pituitary 
HCG levels in the presence of a functioning gonads is 
less than four iu/1." Since the current biologic/immu- 
nological tests cannot be measured below 850 iu/1, 
HCG measurement can be done by radioimmunoassay 
in the four iu/1 to 850 iu/1 range. This gap of HCG levels 
is important for follow up of molar disease as well as 
monitoring choriocarcinoma chemotherapy. Since LH/ 
FSH cannot be differentiated from HCG, measurement 
of B subunit HCG is necessary. The radioimmunoassay 
of the B subunit has becomemore precise and sensitive. 
Automation of the technique enables frequent samples 
to be measured from a large number of patients. Back­
ground interference in the radioimmunoassay HCG has 
been demonstrated in urine and it is essential that serum 
measurement are used. Thus the more sensitive radio­
immunoassay of HCG should be used in the follow up.
The main concern of a molar pregnancy is progres­
sion to invasive mole or to the aggressive malignant 
choriocarcinoma. He majority of trophoblasts(90pc)die 
out spontaneously after an evacuation of the uterus and 
about 10 pc persist. Four pc of molar pregnancies 
develop into choriocarcinoma (4,34) whilst up to 57 pc 
of choriocarcimona arise from hydatidiform mole.13
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